Transcranial Alternating Current Stimulation (tACS) and Its Role in Schizophrenia: A Scoping Review
Clinical Psychopharmacology and Neuroscience · 30.11.2023 · 21 (4) · 634-649
DOI: 10.9758/cpn.22.1042 ↗Kurz gefasst
Scoping Review in der Zeitschrift Clinical Psychopharmacology and Neuroscience, online erschienen am 22.05.2023. Verfasst von Harsh Pathak und 2 weiteren Autor:innen. Beteiligte Einrichtung: InSTAR Program and WISER Neuromodulation Program, Schizophrenia Clinic, Department of Psychiatry, National Institute of Mental Health and Neuroscienc…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust, Department of Biotechnology (DBT) - Wellcome Trust India Alliance, National Research Foundation of Korea.
Abstract (Originalsprache)
Transcranial alternating current stimulation (tACS) may modulate neuronal oscillations by applying sinusoidal alternating current, thereby alleviating associated symptoms in schizophrenia. Considering its possible utility in schizophrenia, we reviewed the literature for tACS protocols administered in schizophrenia and their findings. A scoping review was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline in databases and clinical trial registers. The search resulted in 59 publications. After excluding review articles unrelated to tACS, trials without published results or not involving patients with schizophrenia, 14 studies were included. Among the included studies/case reports only 5 were randomized controlled therapeutic trials. The studies investigated the utility of tACS for clinical and neurobiological outcomes. All studies reported good tolerability with only transient mild side effects. It was administered mostly during the working memory task (such as computerized n-back task, dual back task, and computerized digit symbol substitution task) for schizophrenia patients with cognitive deficits and during resting state while targeting positive symptoms. A possible reduction in hallucinations and delusions using alpha tACS, and improvement in negative and cognitive deficits with theta and gamma tACS were reported. Nevertheless, one of the randomized controlled trials targeting hallucinations was negative and rigorous large-sample studies are lacking for other domains. The current evidence for tACS in schizophrenia is preliminary though promising. In future, more sham controlled randomized trials assessing the effect of tACS on various domains are needed to substantiate these early findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- InSTAR Program and WISER Neuromodulation Program, Schizophrenia Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
ORCID-Profile: Harsh Pathak, Vanteemar S Sreeraj, Ganesan Venkatasubramanian
Förderung
- Wellcome Trust
- Department of Biotechnology (DBT) - Wellcome Trust India Alliance
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Pathak, H., Sreeraj, V. S., & Venkatasubramanian, G. (2023). Transcranial Alternating Current Stimulation (tACS) and Its Role in Schizophrenia: A Scoping Review. Clinical Psychopharmacology and Neuroscience, 21(4), 634-649. https://doi.org/10.9758/cpn.22.1042
Vancouver
Pathak H, Sreeraj VS, Venkatasubramanian G. Transcranial Alternating Current Stimulation (tACS) and Its Role in Schizophrenia: A Scoping Review. Clinical Psychopharmacology and Neuroscience. 2023;21(4):634-649. doi:10.9758/cpn.22.1042
BibTeX
@article{Pathak2023,
author = {Pathak, Harsh and Sreeraj, Vanteemar S and Venkatasubramanian, Ganesan},
title = {Transcranial Alternating Current Stimulation (tACS) and Its Role in Schizophrenia: A Scoping Review},
journal = {Clinical Psychopharmacology and Neuroscience},
year = {2023},
volume = {21},
number = {4},
pages = {634--649},
doi = {10.9758/cpn.22.1042}
}
EUVIMED